ADVA
ADVA (FSE: ADV) today launched a whole new way for communication service providers (CSPs) to drive more revenue from their already deployed fiber networks. With spectrum as a service , CSPs can now slice the optical spectrum in their fiber infrastructure, just like radio spectrum in 5G networks. They can then sell different frequency blocks to different customers, enabling them to fully harness the untapped value in their networks. Powered by ADVA’s FSP 3000 open line system (OLS), spectrum as a service is an entirely new approach for CSPs to utilize vast amounts of unused spectrum. By leveraging ADVA’s coherent optics, programmable flexgrid technology and intelligent network control, CSPs can start selling fully assured and differentiated optical spectrum services to their customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200312005038/en/
“Today we’re introducing a new way for CSPs to tackle skyrocketing data demand and diminishing margins. Optical spectrum in fiber networks can now be sliced and offered as differentiated services to multiple end users. This gives CSPs a completely fresh business case and a brand new area for revenue growth,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “Our unique open line system is the key to realizing the full benefits of the spectrum-as-a-service approach. Its spectrum gateway functionality and advanced optical layer control empower CSPs to elastically allocate optical spectrum to services and deliver virtually unlimited capacity. What’s more, with optical spectrum services, CSPs can put their end customers in control like never before.”
The ADVA FSP 3000 OLS provides the optimum platform for spectrum-as-a-service offerings. It creates an open and scalable optical layer ready to accommodate evolving demand and the latest innovation. With a modular design as well as multiple multiplexer and amplifier options, it's engineered to meet the specific requirements of modern metro, core and DCI applications. The ADVA FSP 3000 OLS removes the limits of the traditional fixed channel grid systems so that unused spectrum can be put to work. This approach also enables operators to take advantage of flexible resource utilization and future-proof their networks by avoiding unnecessary O/E/O conversions.
“Up until now, CSPs have been unable to monetize the vast amounts of unused spectrum in their networks. But thanks to advances in coherent optics, programmable flexgrid technology and intelligent network control, spectrum as a service is now a real and affordable option. CSPs can use the approach to unleash the full value of their fiber assets,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Following multiple spectrum-as-a-service proof-of-concepts involving several partners and spanning different network domains, we're now removing the limits on fiber capacity for CSPs across the world. With this launch, we're unlocking the potential of today's fiber infrastructure and ushering in a new age of flexible, future-proof growth.”
Watch this video for more information on ADVA’s spectrum-as-a-service solution: https://youtu.be/FBCuuvYWN4A .
Further details are also available in these slides: https://adva.li/spectrum-as-a-service-slides .
Learn more about ADVA’s FSP 3000 open line system in this video: https://youtu.be/E_P8_ypxR1w .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200312005038/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom